Global Vaccine and Immunization Research Forum: Opportunities and challenges in vaccine discovery, development, and delivery

Ford, Andrew; Touchette, Nancy; Hall, Bradford; Hwang, Angela; Hombach, Joachim

doi:10.1016/j.vaccine.2015.11.038

Cited by 13 publications

(12 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…TPPs describe the minimally acceptable and aspirational ranges of product features to guide product PLOS ONE development of vaccines, and establish go/no-go criteria for prioritisation and investment by developers. As such, the TSE approach could allow manufacturers to understand country needs, which could be combined with technical considerations such as likelihood of clinical success and manufacturing feasibility to develop more robust TPPs and roadmaps for products with higher chance of country uptake that will ultimately lead to greater public health impact [19]. This study demonstrated the application of MCDA as systematic approach for evaluating the relative value proposition, or trade off, of existing and potential products based on country priorities.…”

Section: Discussionmentioning

confidence: 99%

‘It takes two to tango’: Bridging the gap between country need and vaccine product innovation

et al. 2020

View full text Add to dashboard Cite

Background Despite a growing global commitment to universal health coverage, considerable vaccine coverage and uptake gaps persist in resource-constrained settings. One way of addressing the gaps is by ensuring product innovation is relevant and responsive to the needs of these contexts. Total Systems Effectiveness (TSE) framework has been developed to characterize preferred vaccine attributes from the perspective of country decision-makers to inform research and development (R&D) of products. A proof of concept pilot study took place in Thailand in 2018 to examine the feasibility and usefulness of the TSE approach using a rotavirus hypothetical test-case. Methods The excel-based model used multiple-criteria decision analysis (MCDA) to compare and evaluate five hypothetical rotavirus vaccine products. The model was populated with local data and products were ranked against decision criteria identified by Thai stakeholders. A one-way sensitivity analysis was performed to identify criteria that influenced vaccine ranking. Self-assessment forms were distributed to R&D stakeholders on the usability of the approach and were subsequently analysed. Results The model identified significant parameters that impacted on MCDA rankings. Self-assessment forms revealed that TSE was perceived as being able to encourage closer collaboration between country decision makers and vaccine developers.

show abstract

Section: Discussionmentioning

confidence: 99%

‘It takes two to tango’: Bridging the gap between country need and vaccine product innovation

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Main focus of GVIRF is on current vaccine development specifically for the treatment of human immunodeficiency virus (HIV), tuberculosis (TB), malaria and universal influenza vaccines. 28 On this forum, research strategy and molecular mechanism concerning these vaccines are discussed in detail. HIV is famous for its previous name 'acquired immune deficiency syndrome (AIDS)', which has the abilities of progressively causing failure of the immune system and life-threatening opportunistic infections.…”

Section: Hiv Vaccinesmentioning

confidence: 99%

Novel vaccine design based on genomics data analysis: A review

Shan

Bibi

et al. 2020

Scand J Immunol

View full text Add to dashboard Cite

Modification of pathogenic strains with the passage of time is responsible for evolution in the timeline of vaccine development for last 30 years. Recent advancements in computational vaccinology on the one hand and genome sequencing approaches on the other have generated new hopes in vaccine development. The aim of this review was to discuss the evolution of vaccines, their characteristics and limitations. In this review, we highlighted the evolution of vaccines, from first generation to the current status, pointing out how different vaccines have emerged and different approaches that are being followed up in the development of more rational vaccines against a wide range of diseases. Data were collected using Google Scholar, Web of Science, Science Direct, Web of Knowledge, Scopus and Science Hub, whereas computational tools such as NCBI, GeneMANIA and STRING were used to analyse the pathways of vaccine action. Innovative tools, such as computational tools, recombinant technologies and intra-dermal devices, are currently being investigated in order to improve the immunological response. New technologies enlightened the interactions of host proteins with pathogenic proteins for vaccine candidate development, but still there is a need of integrating transcriptomic and proteomic approaches. Although immunization with genomics data is a successful approach, its advantages must be assessed case by case and its applicability depends on the nature of the agent to be immunized, the nature of the antigen and the type of immune response required to achieve effective protection. 2 of 21 | LU et aL.

show abstract

“…Based on the 2017 assessment report of the GVAP, however, progress continues to be slow and likely most of its 2020 goals may be challenging to reach. 36,37 For instance, indicator data suggest that vaccine coverage levels are not increasing and diseases outbreaks such as measles and others continue to occur. These challenges are due to multiple global, regional and national issues which will require increased global efforts to promote more R&D, increase immunization campaigns, reduce vaccine hesitancy and address the systemic weaknesses that are limiting equitable vaccine access.…”

Section: Business Case and Full Public Health Value Proposition For Nmentioning

confidence: 99%

“Running the Gauntlet”: Formidable challenges in advancing neglected tropical diseases vaccines from development through licensure, and a “Call to Action”

Bottazzi

Hotez

2019

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Translational science for new biotechnologies (e.g. drugs, vaccines, devices, or diagnostics) depend on the development of a robust ‘business case’. This is driven by complex scientific, technical, logistical, financial and operational elements to determine the feasibility and probability of traversing the “valleys of death” leading to licensure. The potential results in terms of profitability and financial realization, called ‘product value proposition’ play a crucial role in establishing incentives for investment during and after development. With this review, our goal is to summarize the challenges in taking vaccines against neglected tropical diseases (NTDs) from development through licensure and provide a perspective that these vaccines can have measurable public health and economic profitability and market success. Understanding these processes and its challenges would open the opportunity to accelerate and advance these essential NTD vaccines through the last mile towards licensure and for the delivery to afflicted populations in low- and middle-income countries.

show abstract

Global Vaccine and Immunization Research Forum: Opportunities and challenges in vaccine discovery, development, and delivery

Cited by 13 publications

References 9 publications

‘It takes two to tango’: Bridging the gap between country need and vaccine product innovation

‘It takes two to tango’: Bridging the gap between country need and vaccine product innovation

Novel vaccine design based on genomics data analysis: A review

“Running the Gauntlet”: Formidable challenges in advancing neglected tropical diseases vaccines from development through licensure, and a “Call to Action”

Contact Info

Product

Resources

About